Summary by Futu AI
Sino Biopharm Limited ("the Company") announced the unaudited interim results for the six months ended June 30, 2024. During the period, the Company's revenue reached RMB 15.87 billion, an 11.1% year-on-year increase; the profit attributable to owners of the parent company was RMB 3.02 billion, a significant 139.7% year-on-year increase. Based on the adjusted basic earnings per share attributable to owners of the parent company, calculated on a per share basis not in accordance with Hong Kong Financial Reporting Standards, the basic earnings per share were RMB 8.34, a 15.0% year-on-year increase. The Board of Directors of the Company announced a distribution of an interim dividend of HK 3 cents per share for the six months ended June 30, 2024. The Company is registered and established in the Cayman Islands, with main business activities including the production, sale, and distribution of modern traditional Chinese medicine and Western pharmaceutical products. The Company's shares are listed on the main board of the Hong Kong Stock Exchange.
